Bionomics

Bionomics Limited (BNO) is a biopharmaceutical company focused on the discovery and development of novel drug candidates focused on the treatment of central nervous system disorders such as anxiety, depression and Alzheimer's Disease.

Bionomics' lead drug candidate BNC210 (currently in Phase 2 for the treatment of agitation) is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co Inc.

Contact Details

31 Dalgleish Street , THEBARTON SA 5031

08 8354 6100

info@bionomics.com.au

www.bionomics.com.au

Lists and Charts

Share price

Bionomics
Closing price for the last 90 trading days

View ASX Chart

Revenue

Rank		Company	#
855^th	-	Bionomics	$5.48m

1332 public companies - non WA ranked by total revenue

View Full List

Company Share Transactions

Company Activity

	NEW ROLE: Connor Bernstein,	01 Mar 2022
	NEW ROLE: Liz Doolin,	25 Aug 2021
	NEW ROLE: Suzanne Irwin, Company Secretary	11 Aug 2021
	NEW ROLE: Miles Davies, Non-Executive Director	11 Aug 2021
	NEW ROLE: Jens Mikkelsen,	24 Nov 2020
	NEW ROLE: Stephen Birrell, Chief Financial Officer	24 Nov 2020
	NEW ROLE: Adrian Hinton, Chief Financial Officer	24 Nov 2020
	NEW ROLE: Paul Rolan, Chief Medical Officer	24 Nov 2020
	NEW ROLE: Steven Lydeamore, Chief Financial Officer	24 Nov 2020

News Articles

Related Information

Access to our data for Bionomics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Bionomics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today